Articles in Point of View

H1 2026 Healthcare Trends: Health Systems Are Buying Infrastructure, Not Apps

Health systems have stopped shopping for point solutions. H1 2026 data show the winners are the platforms that integrate seamlessly into clinical…

July 28, 2026 by Julien de Salaberry Read article

The Q3 Intelligence Window: Why Alpha Briefs Matter Before the Q4 Push

Q3 is the ideal window for healthcare leaders to convert uncertainty into decision-ready intelligence before the commercial, strategic and budget pressures of…

June 26, 2026 by Julien de Salaberry Read article

The €5 billion question: is Europe finally building strategic capital — or still thinking too small?

The European Commission’s new Scaleup Europe Fund is being dismissed as too small. The criticism is understandable. But HealthTech Alpha data suggests…

June 16, 2026 by Julien de Salaberry Read article

Big Tech is no longer experimenting at the edges of healthcare. Microsoft, Amazon, Google, Apple, NVIDIA and Meta are becoming part of healthcare’s infrastructure, AI, data, consumer access and venture partnership layer.

Big Tech is becoming part of the operating system of modern healthcare. From AI and cloud infrastructure to wearables, pharmacy, clinical workflow…

June 15, 2026 by Galen Growth Read article

AI in U.S. Healthcare Operations: Why Health Management Solutions Became the New Infrastructure Layer

Administrative overload, workforce shortages, and operating cost pressure have pushed U.S. healthcare beyond pilots: the United States now accounts for 41% of…

May 12, 2026 by Sara Schmachtenberg Read article

The Execution Decade: Why Clinical Trials Are Pharma’s 2026 R&D Bottleneck

IQVIA’s Global Trends in R&D 2026 confirms what the digital health data has been signalling for two years: pharma’s productivity problem lives…

May 7, 2026 by Julien de Salaberry Read article

Digital health funding in Clinical Trials: Why Execution, Not Discovery, is Pharma’s Next Existential Bottleneck

TL;DR The Bottleneck Has Shifted: TechBio funding surged +75%. Clinical trial funding fell -30%. Trials still consume >50% of total R&D costs.…

March 31, 2026 by Galen Growth Read article

Next Generation Power Players: HealthTech 250 Reveals 50 Emerging Digital Health Startups in Top Clusters

TL;DR A Shortcut to the Next Generation: Amidst a maturing market that saw $29.7 billion in global digital health funding in 2025,…

March 24, 2026 by Galen Growth Read article

The Signal Beneath the Noise: What the 2026 HT250 Tells Investors About Where Digital Health Is Actually Heading

Galen Growth's proprietary ranking of the world's most promising early-stage digital health startups reveals a global sector defined by capital discipline, AI-native…

March 17, 2026 by Galen Growth Read article

Carbon Health: How a US$2.8bn Digital Health unicorn discovered clinics don’t scale like software

TL;DR Carbon Health filed for Chapter 11 protection on 2 February 2026 in the Southern District of Texas as a lender-backed “dual‑track”…

February 26, 2026 by Galen Growth Read article

The Galen Growth HealthTech 250, one year on: separating signal from noise in digital health ventures

One year after selection, the 2025 HealthTech 250 demonstrates exceptional resilience, raising $1.6B, securing 1,001 partnerships, and maintaining a 96% survival rate.…

February 12, 2026 by Galen Growth Read article

2025 Was the Year Europe Got Paid. 2026 Is the Year Europe Must Prove It Was Worth It.

TL;DR Europe Leads Growth: Europe was the fastest-growing region in 2025, with funding rising 15% year-on-year to $6.2 billion, outpacing North America.…

February 3, 2026 by Galen Growth Read article